Brokerages Anticipate Co-Diagnostics Inc (NASDAQ:CODX) to Announce ($0.03) EPS

Shares of Co-Diagnostics Inc (NASDAQ:CODX) have received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokers have set a twelve-month consensus price target of $2.00 for the company and are predicting that the company will post ($0.03) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Co-Diagnostics an industry rank of 79 out of 256 based on the ratings given to its competitors.

Several research analysts have weighed in on CODX shares. HC Wainwright set a $4.00 target price on shares of DURECT and gave the stock a “buy” rating in a research report on Friday, July 19th. Zacks Investment Research upgraded shares of Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 target price on the stock in a research report on Monday, July 8th. Finally, Maxim Group set a $2.00 target price on shares of Co-Diagnostics and gave the stock a “buy” rating in a research report on Thursday, July 11th.

NASDAQ CODX opened at $1.36 on Thursday. Co-Diagnostics has a 52-week low of $0.69 and a 52-week high of $3.88. The business’s 50-day moving average price is $0.93.

Co-Diagnostics (NASDAQ:CODX) last issued its earnings results on Wednesday, May 15th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). Co-Diagnostics had a negative return on equity of 430.95% and a negative net margin of 19,057.66%. As a group, analysts predict that Co-Diagnostics will post -0.09 EPS for the current fiscal year.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc was founded in 2013 and is headquartered in Salt Lake City, Utah.

Recommended Story: Capital Gains Distribution

Get a free copy of the Zacks research report on Co-Diagnostics (CODX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with's FREE daily email newsletter.